I am a scientist, inventor, and entrepreneur. I have invented and pioneered several technologies, ranging from a widely adopted and phase III tested B-cell vaccine platform (Plug-And-Display), a bioconjugation strategies to equip biotherapeutics (GenieTag), to a microbial mineral mining technology.
In 2018 I co-founded Genie Biotech, specializing in bioconjugation technologies.
In 2022, I joined the Applied Biotechnology Laboratory at the Francis Crick Institute, with the intention of leveraging bioengineering and entrepreneurship to develop and deploy new biotechnologies that tackle crucial unaddressed challenges in biology and medicine. I have a special interest in prophylactic interventions, such as vaccines.
In addition to my academic work, I think about new structures for scientific research, how to improve academic training towards industry, and how non-traditional infrastructure can aid early career researchers, like myself, to tackle global challenges.
Selected work
GenieTag Bioconjugation
GenieTag (azidogluconoylation) allows introduction of a single azide functional group to a protein of interest in a simple, quick and non-enzymatic way.
GenieTag is being commercialized by Genie Biotech.
Plug-And-Display Vaccines
Plug-And-Display allows modular decoration of nano- and virus-like particles for inducing antibodies against displayed antigens, and was developed at the University of Oxford in the lab of Mark Howarth.
Plug-And-Display is being commercialised by SpyBiotech, and AdaptVac (in collaboration with Bavarian Nordic).
